UBS Group
ADILW

UBS Group’s Adial Pharmaceuticals Warrant ADILW Stock Holding History

UBS Group’s Portfolio ADILW Stock Details ADILW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,534
Closed -$39 – 10313
2023
Q2 		$39 Buy
+6,534
New +$148 ﹤0.01% 8630
2021
Q4 		– Sell
-2
Closed – – 10988
2021
Q3 		$0 Buy
+2
New +$2 ﹤0.01% 10354
2021
Q2 		– Sell
-4,961
Closed -$3K – 10024
2021
Q1 		$3K Buy
4,961
+1,242
+33% +$824 ﹤0.01% 8556
2020
Q4 		$1K Sell
3,719
-24
-0.6% -$8 ﹤0.01% 8281
2020
Q3 		$1K Sell
3,743
-4,973
-57% -$1.73K ﹤0.01% 7871
2020
Q2 		$2K Sell
8,716
-358
-4% -$93 ﹤0.01% 7687
2020
Q1 		$1K Sell
9,074
-428
-5% -$88 ﹤0.01% 7840
2019
Q4 		$2K Hold
9,502
– – ﹤0.01% 7879
2019
Q3 		$2K Hold
9,502
– – ﹤0.01% 7772
2019
Q2 		$2K Buy
9,502
+2,885
+44% +$988 ﹤0.01% 7654
2019
Q1 		$3K Buy
6,617
+2,536
+62% +$1.85K ﹤0.01% 7369
2018
Q4 		$2K Buy
4,081
+4,080
+408,000% +$1.75K ﹤0.01% 7830
2018
Q3 		$0 Buy
+1
New – ﹤0.01% 8366

UBS Group's ADILW Position: Q3 2023 in Review

UBS Group sold out of Adial Pharmaceuticals Warrant (ADILW) in Q3 2023, closing a stake of 6,534 shares — an estimated $39 sold.

UBS Group first reported a position in ADILW in Q3 2018 and held it in 13 quarters. The position peaked at $3K in Q1 2021. 0 funds tracked by Wall St. Rank hold ADILW as of Q3 2023.

  • UBS Group reported no remaining Adial Pharmaceuticals Warrant position as of Q3 2023 after selling out during the quarter.
  • UBS Group sold 6,534 Adial Pharmaceuticals Warrant shares in Q3 2023, an estimated $39.
  • UBS Group first reported a position in Adial Pharmaceuticals Warrant in Q3 2018 and held it in 13 quarters.
  • UBS Group's Adial Pharmaceuticals Warrant position peaked at $3K in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Adial Pharmaceuticals Warrant as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.